Tumor evasion from T cell surveillance

Journal of Biomedicine and Biotechnology

Volumn 2011, Issue , 2011, Pages

  Töpfer, Katrin ^a   Kempe, Stefanie ^a   Müller, Nadja ^a   Schmitz, Marc ^b   Bachmann, Michael ^b   Cartellieri, Marc ^b   Schackert, Gabriele ^a   Temme, Achim ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENILEUKIN DIFTITOX; DOCETAXEL; FAS LIGAND; FRESOLIMUMAB; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; IMIQUIMOD; INTERLEUKIN 2; IPILIMUMAB; MAGE 3.A1 PEPTIDE; MDX 1106; MELAN A; MONOPHENOL MONOOXYGENASE; MUCIN 1; NA17.A2 PEPTIDE; PAP GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR FUSION PROTEIN; TARP PROTEIN; TRABEDERSEN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; URELUMAB; LYMPHOCYTE ANTIGEN RECEPTOR; PEPTIDE; TUMOR PROTEIN;

ANTIGEN RECOGNITION; APOPTOSIS; BASAL CELL CARCINOMA; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CELL DEATH; CELLULAR IMMUNITY; CLONAL ANERGY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GENETIC ENGINEERING; GLIOMA; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; KIDNEY CARCINOMA; LEUKEMIA; LOW DRUG DOSE; MANTLE CELL LYMPHOMA; MELANOMA; METASTASIS; MOLECULAR MECHANICS; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSTATE ADENOCARCINOMA; REGULATORY T LYMPHOCYTE; REVIEW; SKIN TOXICITY; SOLID TUMOR; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR MICROENVIRONMENT; ANIMAL; IMMUNOLOGY; NEOPLASM; PATHOLOGY; TUMOR ESCAPE;

ANIMALS; DENDRITIC CELLS; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC SURVEILLANCE; NEOPLASM PROTEINS; NEOPLASMS; PEPTIDES; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 84855179131     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2011/918471     Document Type: Review

References (216)

1. Ehrlich P., ber den jetzigen Stand der Karzinomforschung Nederlands Tijdschrift voor Geneeskunde 1909 5 273 290
2. Kaplan D. H., Shankaran V., Dighe A. S., Stockert E., Aguet M., Old L. J., Schreiber R. D., Demonstration of an interferon -dependent tumor surveillance system in immunocompetent mice Proceedings of the National Academy of Sciences of the United States of America 1998 95 13 7556 7561 (Pubitemid 28293291)
3. Street S. E. A., Trapani J. A., MacGregor D., Smyth M. J., Suppression of lymphoma and epithelial malignancies effected by interferon Journal of Experimental Medicine 2002 196 1 129 134 (Pubitemid 34747318)
4. van den Broek M. F., Kgi D., Ossendorp F., Toes R., Vamvakas S., Lutz W. K., Melief C. J. M., Zinkernagel R. M., Hengartner H., Decreased tumor surveillance in perforin-deficient mice Journal of Experimental Medicine 1996 184 5 1781 1790 (Pubitemid 26404469)
5. Shankaran V., Ikeda H., Bruce A. T., White J. M., Swanson P. E., Old L. J., Schreiber R. D., IFN, and lymphocytes prevent primary tumour development and shape tumour immunogenicity Nature 2001 410 6832 1107 1111 (Pubitemid 32391043)
6. Shinkai Y., Rathbun G., Lam K. P., Oltz E. M., Stewart V., Mendelsohn M., Charron J., Datta M., Young F., Stall A. M., Alt F. W., RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement Cell 1992 68 5 855 867
7. Penn I., Post-transplant malignancy. The role of immunosuppression Drug Safety 2000 23 2 101 113 (Pubitemid 30601399)
8. Bower M., Palmieri C., Dhillon T., AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy Current Opinion in Infectious Diseases 2006 19 1 14 19 (Pubitemid 43032434)
9. Kayagaki N., Yamaguchi N., Nakayama M., Hiroshi E., Okumura K., Yagita H., Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs Journal of Experimental Medicine 1999 189 9 1451 1460 (Pubitemid 29227531)
10. Rousalova I., Krepela E., Granzyme B-induced apoptosis in cancer cells and its regulation (review) International Journal of Oncology 2010 37 6 1361 1378
11. Wang R. F., The role of MHC class II-restricted tumor antigens and CD4 + T cells in antitumor immunity Trends in Immunology 2001 22 5 269 276
12. Cella M., Scheidegger D., Palmer-Lehmann K., Lane P., Lanzavecchia A., Alber G., Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation Journal of Experimental Medicine 1996 184 2 747 752 (Pubitemid 26324129)
13. Clarke S. R. M., The critical role of CD40/CD40L in the CD4 - dependent generation of CD8 + T cell immunity Journal of Leukocyte Biology 2000 67 5 607 614
14. Le Page C., Génin P., Baines M. G., Hiscott J., Interferon activation and innate immunity Reviews in Immunogenetics 2000 2 3 374 386 (Pubitemid 32041163)
15. Seliger B., Ruiz-Cabello F., Garrido F., Chapter 7 IFN inducibility of major histocompatibility antigens in tumors Advances in Cancer Research 2008 101 249 276
16. Schreiber R. D., Old L. J., Smyth M. J., Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion Science 2011 331 6024 1565 1570
17. Khong H. T., Restifo N. P., Natural selection of tumor variants in the generation of tumor escape phenotypes Nature Immunology 2002 3 11 999 1005 (Pubitemid 35363649)
18. Palena C., Schlom J., Vaccines against human carcinomas: strategies to improve antitumor immune responses Journal of Biomedicine and Biotechnology 2010 2010
19. Kurts C., Robinson B. W., Knolle P. A., Cross-priming in health and disease Nature Reviews Immunology 2010 10 403 414
20. Matzinger P., The danger model: a renewed sense of self Science 2002 296 5566 301 305 (Pubitemid 34303674)
21. Burgdorf S., Schlz C., Kautz A., Tampé R., Kurts C., Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation Nature Immunology 2008 9 5 558 566 (Pubitemid 351560525)
22. Maurer T., Heit A., Hochrein H., Ampenberger F., O'Keeffe M., Bauer S., Lipford G. B., Vabulas R. M., Wagner H., CpG-DNA aided cross-presentation of soluble antigens by dendritic cells European Journal of Immunology 2002 32 8 2356 2364 (Pubitemid 34965899)
23. Schulz O., Diebold S. S., Chen M., Nslund T. I., Nolte M. A., Alexopoulou L., Azuma Y. T., Flavell R. A., Liljestrm P., Reis E Sousa C., Toll-like receptor 3 promotes cross-priming to virus-infected cells Nature 2005 433 7028 887 892 (Pubitemid 40314900)
24. Shen H., Tesar B. M., Walker W. E., Goldstein D. R., Dual signaling of MyD88 and TRIF is critical for maximal TLR4-induced dendritic cell maturation Journal of Immunology 2008 181 3 1849 1858
25. Barbalat R., Ewald S. E., Mouchess M. L., Barton G. M., Nucleic acid recognition by the innate immune system Annual Review of Immunology 2011 29 185 214
26. Tian J., Avalos A. M., Mao S. Y., Chen B., Senthil K., Wu H., Parroche P., Drabic S., Golenbock D., Sirois C., Hua J., An L. L., Audoly L., La Rosa G., Bierhaus A., Naworth P., Marshak-Rothstein A., Crow M. K., Fitzgerald K. A., Latz E., Kiener P. A., Coyle A. J., Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE Nature Immunology 2007 8 5 487 496 (Pubitemid 46605917)
27. Lande R., Gregorio J., Facchinetti V., Chatterjee B., Wang Y. H., Homey B., Cao W., Wang Y. H., Su B., Nestle F. O., Zal T., Mellman I., Schrder J. M., Liu Y. J., Gilliet M., Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide Nature 2007 449 7162 564 569 (Pubitemid 47525141)
28. Tesniere A., Schlemmer F., Boige V., Kepp O., Martins I., Ghiringhelli F., Aymeric L., Michaud M., Apetoh L., Barault L., Mendiboure J., Pignon J. P., Jooste V., Van Endert P., Ducreux M., Zitvogel L., Piard F., Kroemer G., Immunogenic death of colon cancer cells treated with oxaliplatin Oncogene 2010 29 4 482 491
29. Scaffidi P., Misteli T., Bianchi M. E., Release of chromatin protein HMGB1 by necrotic cells triggers inflammation Nature 2002 418 6894 191 195 (Pubitemid 34773774)
30. Yanai H., Ban T., Wang Z., Choi M. K., Kawamura T., Negishi H., Nakasato M., Lu Y., Hangai S., Koshiba R., Savitsky D., Ronfani L., Akira S., Bianchi M. E., Honda K., Tamura T., Kodama T., Taniguchi T., HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses Nature 2009 462 7269 99 103
31. Apetoh L., Ghiringhelli F., Tesniere A., Criollo A., Ortiz C., Lidereau R., Mariette C., Chaput N., Mira J. P., Delaloge S., André F., Tursz T., Kroemer G., Zitvogel L., The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy Immunological Reviews 2007 220 1 47 59 (Pubitemid 350045573)
32. Kurts C., Kosaka H., Carbone F. R., Miller J. F. A. P., Heath W. R., Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8 + T cells Journal of Experimental Medicine 1997 186 2 239 245 (Pubitemid 27328024)
33. Troy A. J., Summers K. L., Davidson P. J. T., Atkinson C. H., Hart D. N. J., Minimal recruitment and activation of dendritic cells within renal cell carcinoma Clinical Cancer Research 1998 4 3 585 593 (Pubitemid 28193556)
34. Enk A. H., Jonuleit H., Saloga J., Knop J., Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma International Journal of Cancer 1997 73 3 309 316 (Pubitemid 27508890)
35. Nestle F. O., Burg G., Fh J., Wrone-Smith T., Nickoloff B. J., Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen- presenting cells American Journal of Pathology 1997 150 2 641 651 (Pubitemid 27073791)
36. Gabrilovich D. I., Corak J., Ciernik I. F., Kavanaugh D., Carbone D. P., Decreased antigen presentation by dendritic cells in patients with breast cancer Clinical Cancer Research 1997 3 3 483 490 (Pubitemid 27158075)
37. Stumpf M., Hasenburg A., Riener M. O., Jtting U., Wang C., Shen Y., Orlowska-Volk M., Fisch P., Wang Z., Gitsch G., Werner M., Lassmann S., Intraepithelial CD8 - positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes British Journal of Cancer 2009 101 9 1513 1521
38. Jerome K. R., Barnd D. L., Bendt K. M., Boyer C. M., Taylor-Papadimitriou J., McKenzie I. F. C., Bast R. C., Finn O. J., Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells Cancer Research 1991 51 11 2908 2916
39. Baxevanis C. N., Dedoussis G. V. Z., Papadopoulos N. G., Missitzis I., Stathopoulos G. P., Papamichail M., Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer Cancer 1994 74 4 1275 1282 (Pubitemid 24301780)
40. Khong H. T., Wang Q. J., Rosenberg S. A., Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression Journal of Immunotherapy 2004 27 3 184 190 (Pubitemid 39118082)
41. Deschoolmeester V., Baay M., Van Marck E., Weyler J., Vermeulen P., Lardon F., Vermorken J. B., Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients BMC Immunology 2010 11, article 19
42. Meissner M., Reichert T. E., Kunkel M., Gooding W., Whiteside T. L., Ferrone S., Seliger B., Defects in the human leukocyte antigen class I antigen-processing machinery in head and neck squamous cell carcinoma: association with clinical outcome Clinical Cancer Research 2005 11 7 2552 2560 (Pubitemid 40569453)
43. Nie Y., Yang G. Y., Song Y., Zhao X., So C., Liao J., Wang L. D., Yang C. S., DNA hypermethylation is a mechanism for loss of expression of HLA class I genes in human esophageal squamous cell carcinomas Carcinogenesis 2001 22 10 1615 1623 (Pubitemid 32952138)
44. Korkolopoulou P., Kaklamanis L., Pezzella F., Harris A. L., Gatter K. C., Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer British Journal of Cancer 1996 73 2 148 153 (Pubitemid 26028327)
45. Sanda M. G., Restifo N. P., Walsh J. C., Kawakami Y., Nelson W. G., Pardoll D. M., Simons J. W., Molecular characterization of defective antigen processing in human prostate cancer Journal of the National Cancer Institute 1995 87 4 280 285
46. Maleno I., Cabrera C. M., Cabrera T., Paco L., Lpez-Nevot M. A., Collado A., Ferrn A., Garrido F., Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21 Immunogenetics 2004 56 4 244 253 (Pubitemid 39119279)
47. Maleno I., Romero J. M., Cabrera T., Paco L., Aptsiauri N., Cozar J. M., Tallada M., Lpez-Nevot M. A., Garrido F., LOH at 6p21.3 region and HLA class altered phenotypes in bladder carcinomas Immunogenetics 2006 58 7 503 510 (Pubitemid 44025525)
48. Bicknell D. C., Rowan A., Bodmer W. F., 2-Microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors Proceedings of the National Academy of Sciences of the United States of America 1994 91 11 4751 4755
49. Hicklin D. J., Wang Z., Arienti F., Rivoltini L., Parmiani G., Ferrone S., 2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma Journal of Clinical Investigation 1998 101 12 2720 2729 (Pubitemid 28294581)
50. Fonsatti E., Sigalotti L., Coral S., Colizzi F., Altomonte M., Maio M., Methylation-regulated expression of HLA class I antigens in melanoma International Journal of Cancer 2003 105 3 430 431 (Pubitemid 36570059)
51. Soong T. W., Hui K. M., Locus-specific transcriptional control of HLA genes Journal of Immunology 1992 149 6 2008 2020
52. Koch J., Tampé R., The macromolecular peptide-loading complex in MHC class I-dependent antigen presentation Cellular and Molecular Life Sciences 2006 63 6 653 662
53. Manning J., Indrova M., Lubyova B., Pribylova H., Bieblova J., Hejnar J., Simova J., Jandlova T., Bubenik J., Reinis M., Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumours Immunology 2008 123 2 218 227
54. Seliger B., Molecular mechanisms of MHC class I abnormalities and APM components in human tumors Cancer Immunology, Immunotherapy 2008 57 11 1719 1726
55. White L. C., Wright K. L., Felix N. J., Ruffner H., Reis L. F. L., Pine R., Ting J. P. Y., Regulation of LMP2 and TAP1 genes by IRF-1 explains the paucity of CD8 + T cells in IRF-1(-/-) mice Immunity 1996 5 4 365 376 (Pubitemid 26366759)
56. Rodrguez T., Méndez R., Del Campo A., Jiménez P., Aptsiauri N., Garrido F., Ruiz-Cabello F., Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines BMC Cancer 2007 7, article 34
57. Respa A., Bukur J., Ferrone S., Pawelec G., Zhao Y., Wang E., Marincola F. M., Seliger B., Association of IFN- signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines Clinical Cancer Research 2011 17 9 2668 2678
58. Hayashi T., Kobayashi Y., Kohsaka S., Sano K., The mutation in the ATP-binding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon- inducibility of TAP1 and LMP2 Oncogene 2006 25 29 4016 4026 (Pubitemid 44024864)
59. Madhavan M., Srinivas P., Abraham E., Ahmed I., Vijayalekshmi N. R., Balaram P., Down regulation of endothelial adhesion molecules in node positive breast cancer: possible failure of host defence mechanism Pathology and Oncology Research 2002 8 2 125 128 (Pubitemid 34988062)
60. Piali L., Fichtel A., Terpe H. J., Imhof B. A., Gisler R. H., Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma Journal of Experimental Medicine 1995 181 2 811 816
61. Clark R. A., Huang S. J., Murphy G. F., Mollet I. G., Hijnen D., Muthukuru M., Schanbacher C. F., Edwards V., Miller D. M., Kim J. E., Lambert J., Kupper T. S., Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells Journal of Experimental Medicine 2008 205 10 2221 2234
62. Weishaupt C., Munoz K. N., Buzney E., Kupper T. S., Fuhlbrigge R. C., T-cell distribution and adhesion receptor expression in metastatic melanoma Clinical Cancer Research 2007 13 9 2549 2556 (Pubitemid 46788020)
63. Medema J. P., de Jong J., Peltenburg L. T. C., Verdegaal E. M. E., Gorter A., Bres S. A., Franken K. L. M. C., Hahne M., Albar J. P., Melief C. J. M., Offringa R., Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors Proceedings of the National Academy of Sciences of the United States of America 2001 98 20 11515 11520 (Pubitemid 32928760)
64. van Houdt I. S., Oudejans J. J., van den Eertwegh A. J. M., Baars A., Vos W., Bladergroen B. A., Rimoldi D., Muris J. J. F., Hooijberg E., Gundy C. M., Meijer C. J. L. M., Kummer J. A., Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma Clinical Cancer Research 2005 11 17 6400 6407 (Pubitemid 41262972)
65. Mahmood Z., Shukla Y., Death receptors: targets for cancer therapy Experimental Cell Research 2010 316 6 887 899
66. Griffith T. S., Chin W. A., Jackson G. C., Lynch D. H., Kubin M. Z., Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells Journal of Immunology 1998 161 6 2833 2840 (Pubitemid 28425704)
67. Scaffidi C., Schmitz I., Krammer P. H., Peter M. E., The role of c-FLIP in modulation of CD95-induced apoptosis Journal of Biological Chemistry 1999 274 3 1541 1548
68. Nam S. Y., Jung G. A., Hur G. C., Chung H. Y., Kim W. H., Seol D. W., Lee B. L., Upregulation of FLIPs by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers Cancer Science 2003 94 12 1066 1073 (Pubitemid 38035521)
69. Elnemr A., Ohta T., Yachie A., Kayahara M., Kitagawa H., Fujimura T., Ninomiya I., Fushida S., Nishimura G. I., Shimizu K., Miwa K., Human pancreatic cancer cells disable function of Fas receptors at several levels in Fas signal transduction pathway International Journal of Oncology 2001 18 2 311 316
70. Xiao C. W., Yan X., Li Y., Reddy S. A. G., Tsang B. K., Resistance of human ovarian cancer cells to tumor necrosis factor is a consequence of nuclear factor B-mediated induction of Fas-associated death domain-like interleukin-1 -converting enzyme-like inhibitory protein Endocrinology 2003 144 2 623 630 (Pubitemid 36205236)
71. Zhang X., Jin T. G., Yang H., Dewolf W. C., Khosravi-Far R., Olumi A. F., Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer Cancer Research 2004 64 19 7086 7091 (Pubitemid 39331021)
72. Ullenhag G. J., Mukherjee A., Watson N. F. S., Al-Attar A. H., Scholefield J. H., Durrant L. G., Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients Clinical Cancer Research 2007 13 17 5070 5075 (Pubitemid 47502072)
73. Peli J., Schrter M., Rudaz C., Hahne M., Meyer C., Reichmann E., Tschopp J., Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas EMBO Journal 1999 18 7 1824 1831 (Pubitemid 29158526)
74. Volkmann M., Schiff J. H., Hajjar Y., Otto G., Stilgenbauer F., Fiehn W., Galle P. R., Hofmann W. J., Loss of CD95 expression is linked to most but not all p53 mutants in European hepatocellular carcinoma Journal of Molecular Medicine 2001 79 10 594 600 (Pubitemid 32938388)
75. Moller P., Koretz K., Leithauser F., Bruderlein S., Henne C., Quentmeier A., Krammer P. H., Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium International Journal of Cancer 1994 57 3 371 377 (Pubitemid 24168612)
76. Landowski T. H., Qu N., Buyuksal I., Painter J. S., Dalton W. S., Mutations in the Fas antigen in patients with multiple myeloma Blood 1997 90 11 4266 4270 (Pubitemid 27508431)
77. Maeda T., Yamada Y., Moriuchi R., Sugahara K., Tsuruda K., Joh T., Atogami S., Tsukasaki K., Tomonaga M., Kamihira S., Fas gene mutation in the progression of adult T cell leukemia Journal of Experimental Medicine 1999 189 7 1063 1071 (Pubitemid 29169823)
78. Park W. S., Oh R. R., Kim Y. S., Park J. Y., Lee S. H., Shin M. S., Kim S. Y., Kim P. J., Lee H. K., Yoo N. J., Lee J. Y., Somatic mutations in the death domain of the Fas (Apo-I/CD95) gene in gastric cancer Journal of Pathology 2001 193 2 162 168 (Pubitemid 32118126)
79. Shin M. S., Kim H. S., Lee S. H., Park W. S., Su Young Kim, Jik Young Park, Jong Heun Lee, Sang Kyu Lee, Shi Nae Lee, Sang Seol Jung, Ji Youn Han, Hyang Kim, Jung Young Lee, Yoo N. J., Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers Cancer Research 2001 61 13 4942 4946 (Pubitemid 32681514)
80. Cheng J., Zhou T., Liu C., Shapiro J. P., Brauer M. J., Kiefer M. C., Barr P. J., Mountz J. D., Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule Science 1994 263 5154 1759 1762 (Pubitemid 24131584)
81. Midis G. P., Shen Y., Owen-Schaub L. B., Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy Cancer Research 1996 56 17 3870 3874 (Pubitemid 26284729)
82. Ugurel S., Rappl G., Tilgen W., Reinhold U., Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients Clinical Cancer Research 2001 7 5 1282 1286 (Pubitemid 32708681)
83. Pitti R. M., Marsters S. A., Lawrence D. A., Roy M., Kischkel F. C., Dowd P., Huang A., Donahue C. J., Sherwood S. W., Baldwin D. T., Godowski P. J., Wood W. I., Gurney A. L., Hillan K. J., Cohen R. L., Goddard A. D., Botstein D., Ashkenazi A., Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer Nature 1998 396 6712 699 703 (Pubitemid 29003951)
84. Roth W., Isenmann S., Nakamura M., Platten M., Wick W., Kleihues P., Bhr M., Ohgaki H., Ashkenazi A., Weller M., Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis Cancer Research 2001 61 6 2759 2765 (Pubitemid 32685866)
85. Sheikh M. S., Huang Y., Fernandez-Salas E. A., El-Deiry W. S., Friess H., Amundson S., Yin J., Meltzer S. J., Holbrook N. J., Fornace A. J., The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract Oncogene 1999 18 28 4153 4159 (Pubitemid 29363923)
86. Meng R. D., McDonald E. R. III, Sheikh M. S., Fornace A. J. Jr., El-Deiry W. S., The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis Molecular Therapy 2000 1 2 130 144
87. Fisher J. L., Thomas-Mudge R. J., Elliott J., Hards D. K., Sims N. A., Slavin J., Martin T. J., Gillespie M. T., Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically Cancer Research 2006 66 7 3620 3628
88. Holen I., Croucher P. I., Hamdy F. C., Eaton C. L., Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells Cancer Research 2002 62 6 1619 1623 (Pubitemid 34408480)
89. Zou W., Chen L., Inhibitory B7-family molecules in the tumour microenvironment Nature Reviews Immunology 2008 8 6 467 477 (Pubitemid 351733418)
90. Collins A. V., Brodie D. W., Gilbert R. J. C., Iaboni A., Manso-Sancho R., Walse B., Stuart D. I., Van Der Merwe P. A., Davis S. J., The interaction properties of costimulatory molecules revisited Immunity 2002 17 2 201 210 (Pubitemid 35245962)
91. Parry R. V., Chemnitz J. M., Frauwirth K. A., Lanfranco A. R., Braunstein I., Kobayashi S. V., Linsley P. S., Thompson C. B., Riley J. L., CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms Molecular and Cellular Biology 2005 25 21 9543 9553 (Pubitemid 41507854)
92. Hodi F. S., Cytotoxic T-lymphocyte-associated antigen-4 Clinical Cancer Research 2007 13 18 5238 5242 (Pubitemid 47510345)
93. Blank C., Brown I., Peterson A. C., Spiotto M., Iwai Y., Honjo T., Gajewski T. F., PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8 + T cells Cancer Research 2004 64 3 1140 1145 (Pubitemid 38176921)
94. Hamanishi J., Mandai M., Iwasaki M., Okazaki T., Tanaka Y., Yamaguchi K., Higuchi T., Yagi H., Takakura K., Minato N., Honjo T., Fujii S., Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer Proceedings of the National Academy of Sciences of the United States of America 2007 104 9 3360 3365 (Pubitemid 46364164)
95. Ohigashi Y., Sho M., Yamada Y., Tsurui Y., Hamada K., Ikeda N., Mizuno T., Yoriki R., Kashizuka H., Yane K., Tsushima F., Otsuki N., Yagita H., Azuma M., Nakajima Y., Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer Clinical Cancer Research 2005 11 8 2947 2953 (Pubitemid 40525197)
96. Nakanishi J., Wada Y., Matsumoto K., Azuma M., Kikuchi K., Ueda S., Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers Cancer Immunology, Immunotherapy 2007 56 8 1173 1182 (Pubitemid 46763932)
97. Gadiot J., Hooijkaas A. I., Kaiser A. D.M., Van Tinteren H., Van Boven H., Blank C., Overall survival and PD-L1 expression in metastasized malignant melanoma Cancer 2011 117 10 2192 2201
98. Dong H., Strome S. E., Salomao D. R., Tamura H., Hirano F., Flies D. B., Roche P. C., Lu J., Zhu G., Tamada K., Lennon V. A., Cells E., Chen L., Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nature Medicine 2002 8 8 793 800
99. Chemnitz J. M., Parry R. V., Nichols K. E., June C. H., Riley J. L., SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation Journal of Immunology 2004 173 2 945 954 (Pubitemid 38924267)
100. Frigola X., Inman B. A., Lohse C. M., Krco C. J., Cheville J. C., Thompson R. H., Leibovich B., Blute M. L., Dong H., Kwon E. D., Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma Clinical Cancer Research 2011 17 7 1915 1923
101. Kehrl J. H., Wakefield L. M., Roberts A. B., Production of transforming growth factor by human T lymphocytes and its potential role in the regulation of T cell growth Journal of Experimental Medicine 1986 163 5 1037 1050 (Pubitemid 16000407)
102. Ranges G. E., Figari I. S., Espevik T., Palladino M. A. Jr., Inhibition of cytotoxic T cell development by transforming growth factor and reversal by recombinant tumor necrosis factor Journal of Experimental Medicine 1987 166 4 991 998 (Pubitemid 18024241)
103. Robson H., Anderson E., James R. D., Schofield P. F., Transforming growth factor 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients British Journal of Cancer 1996 74 5 753 758 (Pubitemid 26300767)
104. von Rahden B. H. A., Stein H. J., Feith M., Phringer F., Theisen J., Siewert J. R., Sarbia M., Overexpression of TGF- 1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis Molecular Carcinogenesis 2006 45 10 786 794 (Pubitemid 44484989)
105. Bodmer S., Strommer K., Frei K., Siepl C., De Tribolet N., Heid I., Fontana A., Immunosuppression and transforming growth factor- in glioblastoma. Preferential production of transforming growth factor- 2 Journal of Immunology 1989 143 10 3222 3229 (Pubitemid 20010149)
106. Walker R. A., Dearing S. J., Transforming growth factor beta1 in ductal carcinoma in situ and invasive carcinomas of the breast European Journal of Cancer 1992 28 2-3 641 644
107. Hasegawa Y., Takanashi S., Kanehira Y., Tsushima T., Imai T., Okumura K., Transforming growth factor- 1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma Cancer 2001 91 5 964 971
108. di Bari M. G., Lutsiak M. E., Takai S., Mostbck S., Farsaci B., Semnani R. T., Wakefield L. M., Schlom J., Sabzevari H., TGF-beta modulates the functionality of tumor-infiltrating CD8 + T cells through effects on TCR signaling and Spred1 expression Cancer Immunology, Immunotherapy 2009 58 11 1809 1818
109. Thomas D. A., Massagué J., TGF- directly targets cytotoxic T cell functions during tumor evasion of immune surveillance Cancer Cell 2005 8 5 369 380 (Pubitemid 41579832)
110. Walker M. R., Kasprowicz D. J., Gersuk V. H., Bnard A., Van Landeghen M., Buckner J. H., Ziegler S. F., Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4 + CD25 - T cells Journal of Clinical Investigation 2003 112 9 1437 1443 (Pubitemid 38057697)
111. Greenhough A., Smartt H. J. M., Moore A. E., Roberts H. R., Williams A. C., Paraskeva C., Kaidi A., The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment Carcinogenesis 2009 30 3 377 386
112. Pockaj B. A., Basu G. D., Pathangey L. B., Gray R. J., Hernandez J. L., Gendler S. J., Mukherjee P., Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer Annals of Surgical Oncology 2004 11 3 328 339 (Pubitemid 40486775)
113. Baratelli F., Lin Y., Zhu L., Yang S. C., Heuzé-Vourc'h N., Zeng G., Reckamp K., Dohadwala M., Sharma S., Dubinett S. M., Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4 + T cells Journal of Immunology 2005 175 3 1483 1490 (Pubitemid 41023048)
114. Sharma S., Zhu L., Yang S. C., Zhang L., Lin J., Hillinger S., Gardner B., Reckamp K., Strieter R. M., Huang M., Batra R. K., Dubinett S. M., Cyclooxygenase 2 inhibition promotes IFN- -dependent enhancement of antitumor responses Journal of Immunology 2005 175 2 813 819 (Pubitemid 41094963)
115. Adams L., Scott G. K., Weinberg C. S., Biphasic modulation of cell growth by recombinant human galectin-1 Biochimica et Biophysica ActaMolecular Cell Research 1996 1312 2 137 144 (Pubitemid 26227444)
116. Matsumoto R., Matsumoto H., Seki M., Hata M., Asano Y., Kanegasaki S., Stevens R. L., Hirashima M., Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes Journal of Biological Chemistry 1998 273 27 16976 16984 (Pubitemid 28311730)
117. Yamaoka K., Ingendoh A., Tsubuki S., Nagai Y., Sanai Y., Structural and functional characterization of a novel tumor-derived rat galectin-1 having transforming growth factor (TGF) activity: the relationship between intramolecular disulfide bridges and TGF activity Journal of Biochemistry 1996 119 5 878 886
118. Mourad-Zeidan A. A., Melnikova V. O., Wang H., Raz A., Bar-Eli M., Expression profiling of galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry American Journal of Pathology 2008 173 6 1839 1852
119. Rorive S., Belot N., Decaestecker C., Lefranc F., Gordower L., Micik S., Maurage C. A., Kaltner H., Ruchoux M. M., Danguy A., Gabius H. J., Salmon I., Kiss R., Camby I., Galectin-1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchyma GLIA 2001 33 3 241 255 (Pubitemid 32219133)
120. van den Brle F. A., Waltregny D., Castronovo V., Increased expression of galectin-I in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients Journal of Pathology 2001 193 1 80 87 (Pubitemid 32051116)
121. Cindolo L., Benvenuto G., Salavatore P., Pero R., Salvatore G., Mirone V., Prezioso D., Altieri V., Bruni C. B., Chiariotti L., Galectin-1 and galectin-3 expression in human bladder transitional-cell carcinomas International Journal of Cancer 1999 84 1 39 43 (Pubitemid 29059106)
122. Van den Brle F., Califice S., Garnier F., Fernandez P. L., Berchuck A., Castronovo V., Galectin-1 accumulation in the ovary carcinoma peritumoral stroma is induced by ovary carcinoma cells and affects both cancer cell proliferation and adhesion to laminin-1 and fibronectin Laboratory Investigation 2003 83 3 377 386 (Pubitemid 36350999)
123. Jung E. J., Moon H. G., Bok I. C., Jeong C. Y., Joo Y. T., Lee Y. J., Hong S. C., Choi S. K., Ha W. S., Jae W. K., Lee C. W., Jong S. L., Park S. T., Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer International Journal of Cancer 2007 120 11 2331 2338 (Pubitemid 46642118)
124. Perillo N. L., Pace K. E., Seilhamer J. J., Baum L. G., Apoptosis of T cells mediated by galectin-1 Nature 1995 378 6558 736 739 (Pubitemid 126647279)
125. Rabinovich G. A., Iglesias M. M., Modesti N. M., Castagna L. F., Wolfenstein-Todel C., Riera C. M., Sotomayor C. E., Activated rat macrophages produce a galectin-1-like protein that induces apoptosis of T cells: biochemical and functional characterization Journal of Immunology 1998 160 10 4831 4840 (Pubitemid 28215317)
126. Chung C. D., Patel V. P., Moran M., Lewis L. A., Miceli M. C., Galectin-1 induces partial TCR -chain phosphorylation and antagonizes processive TCR signal transduction Journal of Immunology 2000 165 7 3722 3729 (Pubitemid 32057278)
127. Green D. R., Droin N., Pinkoski M., Activation-induced cell death in T cells Immunological Reviews 2003 193 70 81 (Pubitemid 36688041)
128. Hahne M., Rimoldi D., Schrter M., Romero P., Schreier M., French L. E., Schneider P., Bornand T., Fontana A., Lienard D., Cerottini J. C., Tschopp J., Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape Science 1996 274 5291 1363 1366 (Pubitemid 26391458)
129. Niehans G. A., Brunner T., Frizelle S. P., Liston J. C., Salerno C. T., Knapp D. J., Green D. R., Kratzke R. A., Human lung carcinomas express Fas ligand Cancer Research 1997 57 6 1007 1012 (Pubitemid 27138590)
130. Bernstorff W. V., Glickman J. N., Odze R. D., Farraye F. A., Joo H. G., Goedegebuure P. S., Eberlein T. J., Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors: implications for immune privilege and immune escape Cancer 2002 94 10 2552 2560 (Pubitemid 34478067)
131. Mllauer L., Mosberger I., Grusch M., Rudas M., Chott A., Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer Journal of Pathology 2000 190 1 20 30 (Pubitemid 30053349)
132. Arai H., Gordon D., Nabel E. G., Nabel G. J., Gene transfer of Fas ligand induces tumor regression in vivo Proceedings of the National Academy of Sciences of the United States of America 1997 94 25 13862 13867 (Pubitemid 28009675)
133. Kang S. M., Lin Z., Ascher N. L., Stock P. G., Fas ligand expression on islets as well as multiple cell lines results in accelerated neutrophilic rejection Transplantation Proceedings 1998 30 2 538 (Pubitemid 28207289)
134. Drozdzik M., Qian C., Lasarte J. J., Bilbao R., Prieto J., Antitumor effect of allogenic fibroblasts engineered to express Fas ligand (FasL) Gene Therapy 1998 5 12 1622 1630 (Pubitemid 29008332)
135. Ryan A. E., Shanahan F., O'Connell J., Houston A. M., Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo Cancer Research 2005 65 21 9817 9823 (Pubitemid 41541459)
136. Andreola G., Rivoltini L., Castelli C., Huber V., Perego P., Deho P., Squarcina P., Accornero P., Lozupone F., Lugini L., Stringaro A., Molinari A., Arancia G., Gentile M., Parmiani G., Fais S., Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles Journal of Experimental Medicine 2002 195 10 1303 1316 (Pubitemid 34564332)
137. Iero M., Valenti R., Huber V., Filipazzi P., Parmiani G., Fais S., Rivoltini L., Tumour-released exosomes and their implications in cancer immunity Cell Death and Differentiation 2008 15 1 80 88 (Pubitemid 350286175)
138. Shiraki K., Yamanaka T., Inoue H., Kawakita T., Enokimura N., Okano H., Sugimoto K., Murata K., Nakano T., Expression of TNF-related apoptosis-inducing ligand in human hepatocellular carcinoma International Journal of Oncology 2005 26 5 1273 1281
139. Munn D. H., Zhou M., Attwood J. T., Bondarev I., Conway S. J., Marshall B., Brown C., Mellor A. L., Prevention of allogeneic fetal rejection by tryptophan catabolism Science 1998 281 5380 1191 1193 (Pubitemid 28406294)
140. Frumento G., Rotondo R., Tonetti M., Damonte G., Benatti U., Ferrara G. B., Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase Journal of Experimental Medicine 2002 196 4 459 468
141. Lb S., Knigsrainer A., Zieker D., Brcher B. L. D. M., Rammensee H. G., Opelz G., Terness P., IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism Cancer Immunology, Immunotherapy 2009 58 1 153 157
142. Sakaguchi S., Ono M., Setoguchi R., Yagi H., Hori S., Fehervari Z., Shimizu J., Takahashi T., Nomura T., Foxp3 + CD25 + CD4 + natural regulatory T cells in dominant self-tolerance and autoimmune disease Immunological Reviews 2006 212 8 27 (Pubitemid 44116697)
143. Fife B. T., Bluestone J. A., Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways Immunological Reviews 2008 224 1 166 182
144. Hori S., Nomura T., Sakaguchi S., Control of regulatory T cell development by the transcription factor Foxp3 Science 2003 299 5609 1057 1061 (Pubitemid 36222930)
145. Schaefer C., Kim G. G., Albers A., Hoermann K., Myers E. N., Whiteside T. L., Characteristics of CD4 + CD25 + regulatory T cells in the peripheral circulation of patients with head and neck cancer British Journal of Cancer 2005 92 5 913 920 (Pubitemid 40462639)
146. Wolf A. M., Wolf D., Steurer M., Gastl G., Gunsilius E., Grubeck-Loebenstein B., Increase of regulatory T cells in the peripheral blood of cancer patients Clinical Cancer Research 2003 9 2 606 612 (Pubitemid 36182591)
147. Yannelli J. R., Tucker J. A., Hidalgo G., Perkins S., Kryscio R., Hirschowitz E. A., Characteristics of PBMC obtained from leukapheresis products and tumor biopsies of patients with non-small cell lung cancer Oncology Reports 2009 22 6 1459 1471
148. Hiraoka N., Onozato K., Kosuge T., Hirohashi S., Prevalence of Foxp3 + regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions Clinical Cancer Research 2006 12 18 5423 5434 (Pubitemid 44497257)
149. Perez S. A., Karamouzis M. V., Skarlos D. V., Ardavanis A., Sotiriadou N. N., Iliopoulou E. G., Salagianni M. L., Orphanos G., Baxevanis C. N., Rigatos G., Papamichail M., CD4 + CD25 + regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients Clinical Cancer Research 2007 13 9 2714 2721 (Pubitemid 46788040)
150. Ormandy L., Hillemann T., Wedemeyer H., Manns M. P., Greten T. F., Korangy F., Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma Cancer Research 2005 65 6 2457 2464 (Pubitemid 40490158)
151. Curiel T. J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J. R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M. L., Knutson K. L., Chen L., Zou W., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nature Medicine 2004 10 9 942 949 (Pubitemid 39273735)
152. Ichihara F., Kono K., Takahashi A., Kawaida H., Sugai H., Fujii H., Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers Clinical Cancer Research 2003 9 12 4404 4408 (Pubitemid 37248397)
153. Viguier M., Lematre F., Verola O., Cho M. S., Gorochov G., Dubertret L., Bachelez H., Kourilsky P., Ferradini L., Foxp3 expressing CD4 + CD 25high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells Journal of Immunology 2004 173 2 1444 1453 (Pubitemid 38924326)
154. Kobayashi N., Hiraoka N., Yamagami W., Ojima H., Kanai Y., Kosuge T., Nakajima A., Hirohashi S., Foxp3 + regulatory T cells affect the development and progression of hepatocarcinogenesis Clinical Cancer Research 2007 13 3 902 911 (Pubitemid 46340366)
155. Ishida T., Ishii T., Inagaki A., Yano H., Komatsu H., Iida S., Inagaki H., Ueda R., Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege Cancer Research 2006 66 11 5716 5722 (Pubitemid 43927124)
156. Almand B., Resser J. R., Lindman B., Nadaf S., Clark J. I., Kwon E. D., Carbone D. P., Gabrilovich D. I., Clinical significance of defective dendritic cell differentiation in cancer Clinical Cancer Research 2000 6 5 1755 1766 (Pubitemid 30305068)
157. Rodriguez P. C., Hernandez C. P., Morrow K., Sierra R., Zabaleta J., Wyczechowska D. D., Ochoa A. C., L-arginine deprivation regulates cyclin D3 mRNA stability in human T cells by controlling HuR expression Journal of Immunology 2010 185 9 5198 5204
158. Schmielau J., Finn O. J., Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients Cancer Research 2001 61 12 4756 4760 (Pubitemid 32691887)
159. Mueller M. M., Fusenig N. E., Constitutive expression of G-CSF and GM-CSF in human skin carcinoma cells with functional consequence for tumor progression International Journal of Cancer 1999 83 6 780 789
160. Rochet N., Dubousset J., Mazeau C., Zanghellini E., Farges M. F., Stora De Novoin H. S., Chompret A., Delpech B., Cattan N., Frenay M., Gioanni J., Establishment, characterisation and partial cytokine expression profile of a new human osteosarcoma cell line (CAL 72) International Journal of Cancer 1999 82 2 282 285 (Pubitemid 29293789)
161. Wislez M., Fleury-Feith J., Rabbe N., Moreau J., Cesari D., Milleron B., Mayaud C., Antoine M., Soler P., Cadranel J., Tumor-derived granulocyte- macrophage colony-stimulating factor and granulocyte colony-stimulating factor prolong the survival of neutrophils infiltrating bronchoalveolar subtype pulmonary adenocarcinoma American Journal of Pathology 2001 159 4 1423 1433 (Pubitemid 32947972)
162. Bronte V., Chappell D. B., Apolloni E., Cabrelle A., Wang M., Hwu P., Restifo N. P., Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8 + T cell responses by dysregulating antigen-presenting cell maturation Journal of Immunology 1999 162 10 5728 5737 (Pubitemid 29314923)
163. Nagaraj S., Gupta K., Pisarev V., Kinarsky L., Sherman S., Kang L., Herber D. L., Schneck J., Gabrilovich D. I., Altered recognition of antigen is a mechanism of CD8 + T cell tolerance in cancer Nature Medicine 2007 13 7 828 835 (Pubitemid 47038194)
164. Tuyaerts S., Aerts J. L., Corthals J., Neyns B., Heirman C., Breckpot K., Thielemans K., Bonehill A., Current approaches in dendritic cell generation and future implications for cancer immunotherapy Cancer Immunology, Immunotherapy 2007 56 10 1513 1537 (Pubitemid 47094397)
165. Yang L., Carbone D. P., Tumor-host immune interactions and dendritic cell dysfunction Advances in Cancer Research 2004 92 13 27 (Pubitemid 39458111)
166. Molenkamp B. G., Sluijter B. J. R., Van Leeuwen P. A. M., Santegoets S. J. A. M., Meijer S., Wijnands P. G. J. T. B., Haanen J. B. A. G., Van Den Eertwegh A. J. M., Scheper R. J., De Gruijl T. D., Local administration of PF-3512676 CpG-B instigates tumor-specific CD8 + T-cell reactivity in melanoma patients Clinical Cancer Research 2008 14 14 4532 4542
167. Papadavid E., Stratigos A. J., Falagas M. E., Imiquimod: an immune response modifier in the treatment of precancerous skin lesions and skin cancer Expert Opinion on Pharmacotherapy 2007 8 11 1743 1755 (Pubitemid 47296552)
168. Prins R. M., Soto H., Konkankit V., Odesa S. K., Eskin A., Yong W. H., Nelson S. F., Liau L. M., Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy Clinical Cancer Research 2011 17 6 1603 1615
169. Di L. G., Buonerba C., Kantoff P. W., Immunotherapy for the treatment of prostate cancer Nature Reviews Clinical Oncology 2011 8 551 561
170. Foss F., Clinical experience with denileukin diftitox (ONTAK) Seminars in Oncology 2006 33 3 S11 S16
171. Morse M. A., Hobeika A. C., Osada T., Serra D., Niedzwiecki D., Kim Lyerly H., Clay T. M., Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines Blood 2008 112 3 610 618
172. June C. H., Principles of adoptive T cell cancer therapy Journal of Clinical Investigation 2007 117 5 1204 1212 (Pubitemid 46718405)
173. Dudley M. E., Wunderlich J., Nishimura M. I., Yu D., Yang J. C., Topalian S. L., Schwartzentruber D. J., Hwu P., Marincola F. M., Sherry R., Leitman S. F., Rosenberg S. A., Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma Journal of Immunotherapy 2001 24 4 363 373 (Pubitemid 32825868)
174. Dudley M. E., Wunderlich J. R., Yang J. C., Sherry R. M., Topalian S. L., Restifo N. P., Royal R. E., Kammula U., White D. E., Mavroukakis S. A., Rogers L. J., Gracia G. J., Jones S. A., Mangiameli D. P., Pelletier M. M., Gea-Banacloche J., Robinson M. R., Berman D. M., Filie A. C., Abati A., Rosenberg S. A., Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma Journal of Clinical Oncology 2005 23 10 2346 2357 (Pubitemid 46218728)
175. Dudley M. E., Wunderlich J. R., Robbins P. F., Yang J. C., Hwu P., Schwartzentruber D. J., Topalian S. L., Sherry R., Restifo N. P., Hubicki A. M., Robinson M. R., Raffeld M., Duray P., Seipp C. A., Rogers-Freezer L., Morton K. E., Mavroukakis S. A., White D. E., Rosenberg S. A., Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes Science 2002 298 5594 850 854 (Pubitemid 35231542)
176. Rosenberg S. A., Yang J. C., Sherry R. M., Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy Clinical Cancer Research 2011 17 4550 4557
177. Peggs K. S., Quezada S. A., Korman A. J., Allison J. P., Principles and use of anti-CTLA4 antibody in human cancer immunotherapy Current Opinion in Immunology 2006 18 2 206 213 (Pubitemid 43327304)
178. Iwai Y., Ishida M., Tanaka Y., Okazaki T., Honjo T., Minato N., Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade Proceedings of the National Academy of Sciences of the United States of America 2002 99 19 12293 12297
179. Brahmer J. R., Drake C. G., Wollner I., Powderly J. D., Picus J., Sharfman W. H., Stankevich E., Pons A., Salay T. M., McMiller T. L., Gilson M. M., Wang C., Selby M., Taube J. M., Anders R., Chen L., Korman A. J., Pardoll D. M., Lowy I., Topalian S. L., Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates Journal of Clinical Oncology 2010 28 19 3167 3175
180. Kwon E. D., Foster B. A., Hurwitz A. A., Madias C., Allison J. P., Greenberg N. M., Burg M. B., Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy Proceedings of the National Academy of Sciences of the United States of America 1999 96 26 15074 15079 (Pubitemid 30019767)
181. Leach D. R., Krummel M. F., Allison J. P., Enhancement of antitumor immunity by CTLA-4 blockade Science 1996 271 5256 1734 1736 (Pubitemid 26102823)
182. Sarnaik A. A., Weber J. S., Recent advances using anti-CTLA-4 for the treatment of melanoma Cancer Journal 2009 15 3 169 173
183. Blansfield J. A., Beck K. E., Tran K., Yang J. C., Hughes M. S., Kammula U. S., Royal R. E., Topalian S. L., Haworth L. R., Levy C., Rosenberg S. A., Sherry R. M., Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer Journal of Immunotherapy 2005 28 6 593 598 (Pubitemid 41533093)
184. Beck K. E., Blansfield J. A., Tran K. Q., Feldman A. L., Hughes M. S., Royal R. E., Kammula U. S., Topalian S. L., Sherry R. M., Kleiner D., Quezado M., Lowy I., Yellin M., Rosenberg S. A., Yang J. C., Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 Journal of Clinical Oncology 2006 24 15 2283 2289 (Pubitemid 46630658)
185. Hodi F. S., O'Day S. J., McDermott D. F., Weber R. W., Sosman J. A., Haanen J. B., Gonzalez R., Robert C., Schadendorf D., Hassel J. C., Akerley W., Van Den Eertwegh A. J. M., Lutzky J., Lorigan P., Vaubel J. M., Linette G. P., Hogg D., Ottensmeier C. H., Lebbé C., Peschel C., Quirt I., Clark J. I., Wolchok J. D., Weber J. S., Tian J., Yellin M. J., Nichol G. M., Hoos A., Urba W. J., Improved survival with ipilimumab in patients with metastatic melanoma New England Journal of Medicine 2010 363 8 711 723
186. Lee H. W., Park S. J., Choi B. K., Kim H. H., Nam K. O., Kwon B. S., 4-1BB promotes the survival of CD8 + T lymphocytes by increasing expression of Bcl-xL and Bfl-1 Journal of Immunology 2002 169 9 4882 4888 (Pubitemid 35217152)
187. Strck L., Scholz C., Drken B., Daniel P. T., Costimulation by CD137/4-1BB inhibits T cell apoptosis and induces Bcl-xL and c-FLIPshort via phosphatidylinositol 3-kinase and AKT/protein kinase B European Journal of Immunology 2005 35 4 1257 1266 (Pubitemid 40542233)
188. Tomillero A., Moral M. A., Gateways to clinical trials Methods and Findings in Experimental and Clinical Pharmacology 2008 30 7 543 588
189. Croft M., Control of immunity by the TNFR-related molecule OX40 (CD134) Annual Review of Immunology 2010 28 57 78
190. Weinberg A. D., Rivera M. M., Prell R., Morris A., Ramstad T., Vetto J. T., Urba W. J., Alvord G., Bunce C., Shields J., Engagement of the OX-40 receptor in vivo enhances antitumor immunity Journal of Immunology 2000 164 4 2160 2169 (Pubitemid 30108775)
191. Jacobs J. F. M., Punt C. J. A., Lesterhuis W. J., Sutmuller R. P. M., Brouwer H. M. L. H., Scharenborg N. M., Klasen I. S., Hilbrands L. B., Figdor C. G., De Vries I. J. M., Adema G. J., Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients Clinical Cancer Research 2010 16 20 5067 5078
192. Coe D., Begom S., Addey C., White M., Dyson J., Chai J. G., Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy Cancer Immunology, Immunotherapy 2010 59 9 1367 1377
193. Moore K. W., de Waal M. R., Coffman R. L., O'Garra A., Interleukin-10 and the interleukin-10 receptor Annual Review of Immunology 2001 19 683 765 (Pubitemid 32368050)
194. Hau P., Jachimczak P., Schlingensiepen R., Schulmeyer F., Jauch T., Steinbrecher A., Brawanski A., Proescholdt M., Schlaier J., Buchroithner J., Pichler J., Wurm G., Mehdorn M., Strege R., Schuierer G., Villarrubia V., Fellner F., Jansen O., Straube T., Nohria V., Goldbrunner M., Kunst M., Schmaus S., Stauder G., Bogdahn U., Schlingensiepen K. H., Inhibition of TGF- 2 with ap 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies Oligonucleotides 2007 17 2 201 212 (Pubitemid 47124417)
195. Bogdahn U., Hau P., Stockhammer G., Venkataramana N. K., Mahapatra A. K., Suri A., Balasubramaniam A., Nair S., Oliushine V., Parfenov V., Poverennova I., Zaaroor M., Jachimczak P., Ludwig S., Schmaus S., Heinrichs H., Schlingensiepen K.-H., Targeted therapy for high-grade glioma with the TGF- 2 inhibitor trabedersen: results of a randomized and controlled phase IIb study Neuro-Oncology 2011 13 1 132 142
196. DeLong P., Tanaka T., Kruklitis R., Henry A. C., Kapoor V., Kaiser L. R., Sterman D. H., Albelda S. M., Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy Cancer Research 2003 63 22 7845 7852 (Pubitemid 37466718)
197. Morgan R. A., Dudley M. E., Wunderlich J. R., Hughes M. S., Yang J. C., Sherry R. M., Royal R. E., Topalan S. L., Kammula U. S., Restifo N. P., Zheng Z., Nahvi A., De Vries C. R., Rogers-Freezer L. J., Mavroukakis S. A., Rosenberg S. A., Cancer regression in patients after transfer of genetically engineered lymphocytes Science 2006 314 5796 126 129 (Pubitemid 44547756)
198. Johnson L. A., Morgan R. A., Dudley M. E., Cassard L., Yang J. C., Hughes M. S., Kammula U. S., Royal R. E., Sherry R. M., Wunderlich J. R., Lee C. C. R., Restifo N. P., Schwarz S. L., Cogdill A. P., Bishop R. J., Kim H., Brewer C. C., Rudy S. F., VanWaes C., Davis J. L., Mathur A., Ripley R. T., Nathan D. A., Laurencot C. M., Rosenberg S. A., Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen Blood 2009 114 3 535 546
199. Eshhar Z., Waks T., Gross G., Schindler D. G., Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the or subunits of the immunoglobulin and T-cell receptors Proceedings of the National Academy of Sciences of the United States of America 1993 90 2 720 724 (Pubitemid 23028937)
200. Bachmann M., Cartellieri M., Feldmann A., Bippes C., Stamova S., Wehner R., Temme A., Schmitz M., Chimeric antigen receptor-engineered T cells for immunotherapy of cancer Journal of Biomedicine and Biotechnology 2010 2010
201. Park J. R., DiGiusto D. L., Slovak M., Wright C., Naranjo A., Wagner J., Meechoovet H. B., Bautista C., Chang W. C., Ostberg J. R., Jensen M. C., Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma Molecular Therapy 2007 15 4 825 833 (Pubitemid 46432004)
202. Till B. G., Jensen M. C., Wang J., Chen E. Y., Wood B. L., Greisman H. A., Qian X., James S. E., Raubitschek A., Forman S. J., Gopal A. K., Pagel J. M., Lindgren C. G., Greenberg P. D., Riddell S. R., Press O. W., Adoptive immunotherapy for indolent non-hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells Blood 2008 112 6 2261 2271
203. Kochenderfer J. N., Wilson W. H., Janik J. E., Dudley M. E., Stetler-Stevenson M., Feldman S. A., Maric I., Raffeld M., Nathan D. A. N., Lanier B. J., Morgan R. A., Rosenberg S. A., Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 Blood 2010 116 20 4099 4102
204. Hombach A., Sent D., Schneider C., Heuser C., Koch D., Pohl C., Seliger B., Abken H., T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis Cancer Research 2001 61 5 1976 1982 (Pubitemid 32692016)
205. Pul M. A., Straathof K. C., Dotti G., Heslop H. E., Rooney C. M., Brenner M. K., A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells Molecular Therapy 2005 12 5 933 941 (Pubitemid 41614489)
206. Zhao Y., Wang Q. J., Yang S., Kochenderfer J. N., Zheng Z., Zhong X., Sadelain M., Eshhar Z., Rosenberg S. A., Morgan R. A., A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity Journal of Immunology 2009 183 9 5563 5574
207. Liu K., Rosenberg S. A., Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity Journal of Immunology 2001 167 11 6356 6365 (Pubitemid 33081567)
208. Charo J., Finkelstein S. E., Grewal N., Restifo N. P., Robbins P. F., Rosenberg S. A., Bcl-2 overexpression enhances tumor-specific T-cell survival Cancer Research 2005 65 5 2001 2008 (Pubitemid 40478630)
209. Di Stasi A., De Angelis B., Rooney C. M., Zhang L., Mahendravada A., Foster A. E., Heslop H. E., Brenner M. K., Dotti G., Savoldo B., T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model Blood 2009 113 25 6392 6402
210. Yu J. S., Liu G., Ying H., Yong W. H., Black K. L., Wheeler C. J., Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma Cancer Research 2004 64 14 4973 4979 (Pubitemid 38924545)
211. Arlen P. M., Pazdur M., Skarupa L., Rauckhorst M., Gulley J. L., A ramdomized phase II study of docetaxel alone or in combination with PANVAC-V (Vaccinia) and PANVAC-F (Fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229) Clinical Breast Cancer 2006 7 2 176 179 (Pubitemid 44044019)
212. Oh S., Terabe M., Pendleton C. D., Bhattacharyya A., Bera T. K., Epel M., Reiter Y., Phillips J., Linehan W. M., Kasten-Sportes C., Pastan I., Berzofsky J. A., Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells Cancer Research 2004 64 7 2610 2618 (Pubitemid 38523919)
213. Kirkwood J. M., Lee S., Moschos S., Albertini M. R., Michalak J. C., Sander C., Whiteside T., Butterfield L. H., Weiner L., Immunogenicity and antitumor effects of vaccination with peptide vaccine +/- granulocyte-monocyte colony-stimulating factor and/or IFIN- 2b in advanced metastatic melanoma: eastern cooperative oncology group phase II trial E1696 Clinical Cancer Research 2009 15 4 1443 1451
214. Sanderson K., Scotland R., Lee P., Liu D., Groshen S., Snively J., Sian S., Nichol G., Davis T., Keler T., Yellin M., Weber J., Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stages III and IV melanoma Journal of Clinical Oncology 2005 23 4 741 750 (Pubitemid 46224173)
215. Rousseau R. F., Biagi E., Dutour A., Yvon E. S., Brown M. P., Lin T., Mei Z., Grilley B., Popek E., Heslop H. E., Gee A. P., Krance R. A., Popat U., Carrum G., Margolin J. F., Brenner M. K., Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation Blood 2006 107 4 1332 1341 (Pubitemid 43242366)
216. Atchison E., Eklund J., Martone B., Wang L., Gidron A., MacVicar G., Rademaker A., Goolsby C., Marszalek L., Kozlowski J., Smith N., Kuzel T. M., A pilot study of denileukin diftitox (DD) in combination with high-dose interleukin-2 (IL-2) for patients with metastatic renal cell carcinoma (RCC) Journal of Immunotherapy 2010 33 7 716 722